Fluorimetric determination of rivastigmine in rat plasma by a reverse phase - High performance liquid chromatographic method: Application to a pharmacokinetic study

A. Karthik, G.S. Subramanian, M. Surulivelrajan, A. Ranjithkumar, S.B. Kamat

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A sensitive and selective high performance liquid chromatographic (HPLC) method was developed and validated for the rapid quantification of rivastigmine (CAS 123441-03-2) in micro quantity in rat plasma samples. The chromatographic separation was achieved with a reverse phase monomeric column C 18 (4.6 x 250 mm, 5 μm) and the mobile phase consisted of acetonitrile and 20 mmol/L phosphate buffer pH 3.0 (25:75) with a flow rate of 1 mL/min. The effluents were measured by fluorimetric detection with excitation and emission wavelengths at 220 nm and 293 nm, respectively. The calibration curve was linear (r 2 >0.99) ranging from 25-3000 ng/mL and the lower limit of quantification was 25 ng/mL. The method was validated with excellent sensitivity, selectivity, accuracy, precision, recovery and stability. The method has been successfully applied in a pharmacokinetic study of rivastigmine in rats. © ECV Editio Cantor Verlag.
Original languageEnglish
Pages (from-to)205-210
Number of pages6
JournalArzneimittel-Forschung/Drug Research
Volume58
Issue number5
Publication statusPublished - 2008

Fingerprint

Rivastigmine
Pharmacokinetics
Calibration
Buffers
Phosphates

Cite this

@article{56fc8813c589439eb537b4af0268ce52,
title = "Fluorimetric determination of rivastigmine in rat plasma by a reverse phase - High performance liquid chromatographic method: Application to a pharmacokinetic study",
abstract = "A sensitive and selective high performance liquid chromatographic (HPLC) method was developed and validated for the rapid quantification of rivastigmine (CAS 123441-03-2) in micro quantity in rat plasma samples. The chromatographic separation was achieved with a reverse phase monomeric column C 18 (4.6 x 250 mm, 5 μm) and the mobile phase consisted of acetonitrile and 20 mmol/L phosphate buffer pH 3.0 (25:75) with a flow rate of 1 mL/min. The effluents were measured by fluorimetric detection with excitation and emission wavelengths at 220 nm and 293 nm, respectively. The calibration curve was linear (r 2 >0.99) ranging from 25-3000 ng/mL and the lower limit of quantification was 25 ng/mL. The method was validated with excellent sensitivity, selectivity, accuracy, precision, recovery and stability. The method has been successfully applied in a pharmacokinetic study of rivastigmine in rats. {\circledC} ECV Editio Cantor Verlag.",
author = "A. Karthik and G.S. Subramanian and M. Surulivelrajan and A. Ranjithkumar and S.B. Kamat",
note = "Cited By :9 Export Date: 10 November 2017 CODEN: ARZNA Correspondence Address: Subramanian, G. S.; Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal. 576104, India; email: ganrajesh@gmail.com Chemicals/CAS: acetonitrile, 75-05-8; rivastigmine, 129101-54-8; venlafaxine, 93413-69-5; Neuroprotective Agents; Phenylcarbamates; rivastigmine, 123441-03-2 Manufacturers: Torrent, India References: Cummings, J.L., Cole, G., Alzheimer disease (2002) JAMA, 287, pp. 2335-2338; Shukla, V.K., Nicolass, O., Doug, C., Pathology of Alzheimer disease (2000) Tech Rep, 11, pp. 1-64; Ronald, J.P., Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease (1998) Clin Ther, 20 (4), pp. 634-637; Bowen, D.M., Francis, P.T., Chessel, I.P., Webster, M.T., (1995) Alzheimer's Disease Clinical and Treatment Perspectives, , Chichester England, John Wiley & Sons;; Srinivasu, M.K., Mallikarjuna Rao, B., Shyam, Sundar Reddy, B., Rajeneder Kumar, P., Chandrasekhar, K.B., Pradeep, K., A validated chiral liquid chromatographic method for the enantiomeric separation of rivastigmine hydrogen tartarate, a cholinesterase inhibitor (2005) J Pharm Biomed Anal, 38, pp. 320-325; Pommier, F., Frigola, R., Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry (2003) J Chromatogr B, 784, pp. 301-313; Enz, A., Chappuis, A., Dattler, A., A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry (2004) Biomed Chromatogr, 18 (3), pp. 160-166; Frankfort, S.V., Ouwehand, M., van Maanen, M.J., Rosing, H., Tulner, L.R., Beijnen, J.H., A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry (2006) Rapid Commun Mass Spectrom, 20 (22), pp. 3330-3336; Bhatt J, Subbaiah G, Kampli S, Shah B.Nigam S, Patel M, et al. A rapid and sensitive liquid chromatography - tandem mass spectrometry (LC - MS/MS) method for the estimation of rivastigmine in human plasma. J Chromatogr B. 2007; 852:115-121; Yunfei, S., Chunhui, D., Zhen, L., Taomin, H., Bei, Y., Gengli, D., Headspace solid-phase microextraction and capillary gas chromatographic-mass spectrometric determination of rivastigmine in canine plasma samples (2004) J Chromatogr B, 806, pp. 271-276; Mallikarjuna Rao, B., Srinivasu, M.K., Neelu, B., Ravi, R., Pradeep, M., Om Reddy, G., A stability indicating LC method for rivastigmine hydrogen tartrate (2005) J Pharm Biomed Anal, 37, pp. 57-63; Kavalirova, A., Pospisilova, M., Karlicek, R., Enantiomeric analysis of rivastigmine in pharmaceuticals by cyclodextrin-modified capillary zone electrophoresis (2004) Anal Chim Acta, 525, pp. 43-51; Guidance for Industry, Bioanalytical Method Validation, , http://www.fda.gov/cder/guidance/4252fnl.pdf, Food and Drug Administration, Center for Drug Evaluation and Research, May 2001. Available at",
year = "2008",
language = "English",
volume = "58",
pages = "205--210",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "5",

}

Fluorimetric determination of rivastigmine in rat plasma by a reverse phase - High performance liquid chromatographic method: Application to a pharmacokinetic study. / Karthik, A.; Subramanian, G.S.; Surulivelrajan, M.; Ranjithkumar, A.; Kamat, S.B.

In: Arzneimittel-Forschung/Drug Research, Vol. 58, No. 5, 2008, p. 205-210.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fluorimetric determination of rivastigmine in rat plasma by a reverse phase - High performance liquid chromatographic method: Application to a pharmacokinetic study

AU - Karthik, A.

AU - Subramanian, G.S.

AU - Surulivelrajan, M.

AU - Ranjithkumar, A.

AU - Kamat, S.B.

N1 - Cited By :9 Export Date: 10 November 2017 CODEN: ARZNA Correspondence Address: Subramanian, G. S.; Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal. 576104, India; email: ganrajesh@gmail.com Chemicals/CAS: acetonitrile, 75-05-8; rivastigmine, 129101-54-8; venlafaxine, 93413-69-5; Neuroprotective Agents; Phenylcarbamates; rivastigmine, 123441-03-2 Manufacturers: Torrent, India References: Cummings, J.L., Cole, G., Alzheimer disease (2002) JAMA, 287, pp. 2335-2338; Shukla, V.K., Nicolass, O., Doug, C., Pathology of Alzheimer disease (2000) Tech Rep, 11, pp. 1-64; Ronald, J.P., Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease (1998) Clin Ther, 20 (4), pp. 634-637; Bowen, D.M., Francis, P.T., Chessel, I.P., Webster, M.T., (1995) Alzheimer's Disease Clinical and Treatment Perspectives, , Chichester England, John Wiley & Sons;; Srinivasu, M.K., Mallikarjuna Rao, B., Shyam, Sundar Reddy, B., Rajeneder Kumar, P., Chandrasekhar, K.B., Pradeep, K., A validated chiral liquid chromatographic method for the enantiomeric separation of rivastigmine hydrogen tartarate, a cholinesterase inhibitor (2005) J Pharm Biomed Anal, 38, pp. 320-325; Pommier, F., Frigola, R., Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry (2003) J Chromatogr B, 784, pp. 301-313; Enz, A., Chappuis, A., Dattler, A., A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry (2004) Biomed Chromatogr, 18 (3), pp. 160-166; Frankfort, S.V., Ouwehand, M., van Maanen, M.J., Rosing, H., Tulner, L.R., Beijnen, J.H., A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry (2006) Rapid Commun Mass Spectrom, 20 (22), pp. 3330-3336; Bhatt J, Subbaiah G, Kampli S, Shah B.Nigam S, Patel M, et al. A rapid and sensitive liquid chromatography - tandem mass spectrometry (LC - MS/MS) method for the estimation of rivastigmine in human plasma. J Chromatogr B. 2007; 852:115-121; Yunfei, S., Chunhui, D., Zhen, L., Taomin, H., Bei, Y., Gengli, D., Headspace solid-phase microextraction and capillary gas chromatographic-mass spectrometric determination of rivastigmine in canine plasma samples (2004) J Chromatogr B, 806, pp. 271-276; Mallikarjuna Rao, B., Srinivasu, M.K., Neelu, B., Ravi, R., Pradeep, M., Om Reddy, G., A stability indicating LC method for rivastigmine hydrogen tartrate (2005) J Pharm Biomed Anal, 37, pp. 57-63; Kavalirova, A., Pospisilova, M., Karlicek, R., Enantiomeric analysis of rivastigmine in pharmaceuticals by cyclodextrin-modified capillary zone electrophoresis (2004) Anal Chim Acta, 525, pp. 43-51; Guidance for Industry, Bioanalytical Method Validation, , http://www.fda.gov/cder/guidance/4252fnl.pdf, Food and Drug Administration, Center for Drug Evaluation and Research, May 2001. Available at

PY - 2008

Y1 - 2008

N2 - A sensitive and selective high performance liquid chromatographic (HPLC) method was developed and validated for the rapid quantification of rivastigmine (CAS 123441-03-2) in micro quantity in rat plasma samples. The chromatographic separation was achieved with a reverse phase monomeric column C 18 (4.6 x 250 mm, 5 μm) and the mobile phase consisted of acetonitrile and 20 mmol/L phosphate buffer pH 3.0 (25:75) with a flow rate of 1 mL/min. The effluents were measured by fluorimetric detection with excitation and emission wavelengths at 220 nm and 293 nm, respectively. The calibration curve was linear (r 2 >0.99) ranging from 25-3000 ng/mL and the lower limit of quantification was 25 ng/mL. The method was validated with excellent sensitivity, selectivity, accuracy, precision, recovery and stability. The method has been successfully applied in a pharmacokinetic study of rivastigmine in rats. © ECV Editio Cantor Verlag.

AB - A sensitive and selective high performance liquid chromatographic (HPLC) method was developed and validated for the rapid quantification of rivastigmine (CAS 123441-03-2) in micro quantity in rat plasma samples. The chromatographic separation was achieved with a reverse phase monomeric column C 18 (4.6 x 250 mm, 5 μm) and the mobile phase consisted of acetonitrile and 20 mmol/L phosphate buffer pH 3.0 (25:75) with a flow rate of 1 mL/min. The effluents were measured by fluorimetric detection with excitation and emission wavelengths at 220 nm and 293 nm, respectively. The calibration curve was linear (r 2 >0.99) ranging from 25-3000 ng/mL and the lower limit of quantification was 25 ng/mL. The method was validated with excellent sensitivity, selectivity, accuracy, precision, recovery and stability. The method has been successfully applied in a pharmacokinetic study of rivastigmine in rats. © ECV Editio Cantor Verlag.

M3 - Article

VL - 58

SP - 205

EP - 210

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 5

ER -